Vital Therapies, Inc., a biotechnology company based in California, has reportedly entered into a definitive collaboration agreement with Immunic AG, a Germany-based private clinical-stage biotechnology company. Under the terms of the agreement, Vital Therapies is expected to purchase all the outstanding shares in Immunic in …
Paragon Genomics, Inc., has recently announced a worldwide partnership with the subsidiary of BGI Group, MGI Tech Co., Ltd. Apparently, MGI would be distributing the CleanPlex® NGS Panels from Paragon Genomics for using them with the sequencing platforms of MGI around the world, except the …
In a recent turn of events, Merck & NGM Biopharmaceuticals Inc. jointly declared that Merck is reportedly exercising its options to license its NGM313 drug that is presently being examined for treating nonalcoholic steatohepatitis as well as type 2 diabetes. As per trusted sources, this …
Biotech firm Merus N.V. has announced that the company has agreed to provide an exclusive license to Betta Pharmaceuticals Co. Ltd. for developing and commercializing Merus Biclonics® MCLA-129 in China. Under the terms of the agreement, Merus would retain all the rights outside of China …
Biotechnology firm Cybrexa Therapeutics, that was developing a new class of cancer therapeutics via its tumor targeting platform alphalex™, has recently announced that the company chose CBX-11 as the leading clinical development candidate for treating patients with various types of solid tumors. Apparently, the company …
The breakthrough will help prevent incapacitating tremors or seizures in patients with diverse neurological conditions. Researchers at the University of California (UC) have recently developed a wireless device that can effectively stimulate the brain with electric current, delivering fine-tuned treatments for patients with diseases like …
The draft National Commission for Indian Systems of Medicine Bill, 2018, that was formed to replace the Central Council for Indian Medicine, which is current regulatory body for medicines in India, has recently been approved by the Union Cabinet. An official statement declared that the …
Perlara, the U.S. based biotech public benefit corporation that is dedicated to discovering cures for rare diseases, recently announced a partnership with Rambam Medical Center in Israel and Dr. Karl Skorecki, a leading kidney disease researcher and nephrologist, to co-develop a PerlQuest into APOL1 kidney disease. For …
Reports confirm that the leading provider of clinical data management technology, OmniComm Systems, Inc., has announced a partnership with pharmaceutical IT solutions firm Hitachi Inspharma. Apparently, under the terms of the partnership, both the companies would work together for providing eClinical solutions to life science …
